Target intelligence / Profile preview

C-X-C motif chemokine ligand 10 (CXCL10) (CXCL10)

Target
CXCL10
Molecular classification
Chemokine, Cytokine, CXC family
01

Overview

C-X-C motif chemokine ligand 10 (CXCL10), historically known as Interferon-gamma inducible Protein 10kDa (IP-10), is a potent pro-inflammatory chemokine belonging to the CXC family. It is primarily secreted by various cell types, including monocytes, endothelial cells, and fibroblasts, in direct response to Interferon-gamma (IFN-g) (UniProt P02778). CXCL10 functions as a specific ligand for the G protein-coupled receptor CXCR3, which is predominantly expressed on Th1-type T cells, natural killer (NK) cells, and macrophages. This interaction is critical for the directed migration and recruitment of these immune cells to sites of infection and chronic inflammation (NCBI Gene ID: 3627). Beyond its role in leukocyte trafficking, CXCL10 also possesses angiostatic properties, allowing it to inhibit neovascularization. In clinical contexts, elevated levels of CXCL10 are associated with the pathogenesis of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, making it a viable therapeutic target. Drugs like Eldelumab have been developed to neutralize CXCL10 to disrupt the cycle of chronic inflammatory cell recruitment (PMID: 25484347).

Other names
Interferon-gamma-inducible protein 10IP-10Small-inducible cytokine B10INP10SCYB10Gamma-IP10
02

Mechanism of action

Monoclonal antibody neutralization of the chemokine ligand to prevent its interaction with the CXCR3 receptor, thereby inhibiting the recruitment of Th1-type inflammatory cells to diseased tissues (PMID: 25484347).

03

Biological functions

ChemotaxisImmune responseAngiostasisSignal transductionCell proliferation
04

Disease associations

InflammationRheumatoid arthritisInflammatory bowel diseaseType 1 diabetesInfectionAutoimmune diseasePsoriasisHepatitis CCOVID-19
05

Safety considerations

Increased risk of infection due to suppressed immune cell recruitmentPotential for generalized immunosuppressionDevelopment of anti-drug antibodies (ADAs)Injection site reactions
06

Interacting drugs

Eldelumab

3 more in the full profile.

07

Biomarkers

Serum CXCL10/IP-10 levelsSynovial fluid CXCL10 concentrationHepatitis C treatment response marker (PMID: 21356004)Tuberculosis diagnostic marker (QuantiFERON-TB Gold alternative)

Beyond the preview

Go deeper on C-X-C motif chemokine ligand 10 (CXCL10) (CXCL10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-X-C motif chemokine ligand 10 (CXCL10) (CXCL10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call